Covid-19 vaccines protection against hospitalization and ICU effectiveness dropping over time: results in different studies

As millions of eligible people consider getting a booster shot, many are wondering what the data tells us about the effectiveness of the vaccines, and how much their protection might be waning. The good news is that a growing body of research shows that the vaccines authorized remain highly protective against severe disease and hospitalization

Read More


SARS-CoV-2 uses sugars to invade human cells, new study by University of Alberta shows

Understanding the process could help scientists look out for new, more infectious variants. Sugars found on the surface of human cells influence COVID-19 infection, according to a University of Alberta-led study that is one of the first to observe this relationship and suggests that cells in the brain might be particularly susceptible. “The idea here is that

Read More


Novel mesenchymal stem cell therapy approach proves effective in treating COVID-19

An international team of researchers has advanced a new therapeutic approach using stem cells to treat COVID-19. Despite many advances in treating the COVID-19 virus there remains no specific cure for patients with infection. This is especially the case with hospitalised patients who end up in the ICU requiring mechanical ventilation support. Key members of

Read More


A prospective cohort study on the long term effects of COVID-19: new disability, functional outcomes and return to work at 6 months

A recent Monash University study has found six months after recovering from COVID-19 critical illness, one in five people had died, and almost 40 per cent of survivors had a new disability. Led by Professor Carol Hodgson, the study looked at COVID-19 critical illness across Australia between March 6 and October 4, 2020, measuring mortality, new

Read More


BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age evaluation paper published in NEJM

Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age. A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6

Read More


Pfizer’s novel COVID-19 oral antiviral protease inhibitor reduced risk of hospitalization or death by 89% in interm analysis of Phase 2/3 EPIC-HR study

PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19 In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo Pfizer plans to submit the data as

Read More


Oxford University researchers uncover gene that doubles risk of death from COVID-19

Scientists at Oxford University have identified the gene responsible for doubling the risk of respiratory failure from COVID-19. Sixty percent of people with South Asian ancestry carry the high-risk genetic signal, partly explaining the excess deaths seen in some UK communities, and the impact of COVID-19 in the Indian subcontinent. Previous work has already identified

Read More


Breakthrough Infection Study Compares Decline in Covid-19 Vaccine Effectiveness and Consequences for Mortality

A new study in the leading journal Science reviewed COVID-19 breakthrough infections among 780,225 Veterans, finding that vaccine protection declined from 87.9% to 48.1% during the 2021 Delta surge in the U.S. The researchers from PHI, the Veterans Affairs Medical Center and the University of Texas Health Science Center found a dramatic decline in effectiveness

Read More